Healthcare

• Novo committed to scale oral Wegovy manufacturing tenfold by 2030, opening potential peptide overflow work for integrated Indian CDMOs such as Divi’s.
• Oral semaglutide is far more peptide-intensive per patient than injectable Wegovy, so capacity scale-up raises demand for fragments, building blocks and cost-efficient CDMO supply.
• Treat oral Wegovy as optionality only; Lilly tirzepatide remains Divi’s core peptide opportunity, and Divi’s stays our top India Pharma pick.

• Hexagon Nutrition Limited (HEXAGON IN) is a differentiated, research-driven pure-play nutraceutical and clinical nutrition manufacturer operating across three core pillars: Micronutrient Premixes, Branded Clinical & Wellness Nutrition, and Therapeutic Malnutrition Formulations.
• Financial performance has demonstrated strong operating leverage, with revenue growing from INR 2,974.52M in 2024 to INR 3,826.28M in 2026 (a 13.42% 2-year CAGR) and net profit expanding over 3x from INR 122.89M to INR 379.37M, supported by a 1,314 bps expansion in gross margin to 32.15%.
• Trading at an attractive valuation relative to broader healthcare and wellness peers, Hexagon is positioned to capitalize on structural tailwinds including mandatory food fortification policies, expanding clinical nutrition adoption in acute/chronic care, and international expansion across emerging markets.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Oura is an always-on health intelligence platform transforming how people understand and manage health. Its Oura Ring captures biometric data, offering a recurring membership for personalized health insights.
• Oura had 5.0 million Paid Members and approximately 85% 12-Month Paid Member Retention as of June 30, 2026. Revenue was $1,214.5 million.
• Total revenue was $1,214,506 and net income was $60,768 for the nine months ended June 30, 2026. Total stockholders’ deficit was $(1,617,734).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Abbott’s second quarter of 2026 results showed a 4.8% comparable sales growth, marking an acceleration from the previous two quarters, alongside adjusted earnings per share (EPS) of $1.31 which surpassed both the midpoint of company guidance and consensus estimates.
• Management reaffirmed full-year guidance with expected comparable sales growth of 6.5% to 7.5% and raised the EPS range to $5.45–$5.60.
• The company highlighted progress in its product pipeline, including enrollment completion in the TECTONIC coronary IVL trial, an FDA submission for the Amulet 360 device, and obtaining CE Mark for Libre Duo, a dual glucose-ketone sensor.

• GRAIL suddenly became one of healthcare’s most closely watched stocks after its shares surged nearly 34% to $107.97 on September 21, following FDA briefing documents that raised investor expectations ahead of a September 23 advisory committee review of Galleri.
• The blood test searches for cancer-associated DNA methylation patterns and is designed to detect signals from more than 50 types of cancer using a single blood draw, while also predicting where a detected signal may have originated.
• FDA reviewers reportedly raised no major outstanding concerns around analytical performance, study design, or primary safety, although the agency is asking outside experts to consider whether Galleri’s performance supports calling it an “early detection” test.

• Intuitive Surgical reported a solid second quarter in 2026 with several positive operational and financial indicators, alongside some market-specific challenges reflective of broader healthcare dynamics.
• The company saw total procedure volume increase by 16%, including a 15% growth in da Vinci system procedures and a 36% rise in Ion platform procedures.
• The global installed base expanded by 12% for da Vinci systems and 21% for Ion systems, totaling nearly 13,000 systems worldwide by quarter-end.

• Eisai Co Ltd (4523 JP) shares advanced ~30% from June lows. Stronger-than-expected Q1FY27 financial result and value maximization initiatives of Leqembi are mainly driving the shares. 
• Eisai has reported better-than-anticipated Q1FY27 result, with revenue and operating profit reaching 27% and 35% of FY27 full-year forecast, driven by the strong performance 3L major products and favorable Fx.
• In near-term, Eisai’s growth will be Leqembi centered. For FY27, Eisai has guided for Leqembi revenue of ¥144B (up 64% YoY), supported by Leqembi Iqlik and blood-based biomarker (BBM).

• Becton, Dickinson and Company reported a third-quarter fiscal 2026 revenue of $5 billion, reflecting a 4.4% increase on a foreign exchange-neutral basis and driven by broad-based growth across over 90% of its portfolio.
• Key growth was observed in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, peripheral vascular disease, and pharmacy automation through the Rowa platform.
• U.S. Medical Diagnostic Systems (MDS) and Specimen Management showed strong performance fueled by utilization recovery and share gains, partially offset by expected headwinds in Alaris and vaccine sales in China.

• Edwards Lifesciences reported stronger-than-expected second quarter 2026 financial results, delivering total sales growth of 12.5% year-over-year to $1.74 billion, underpinned by broad-based performance across its structural heart therapy portfolio and geographical regions.
• The company raised its full-year sales guidance to 10% to 11%, reflecting confidence in sustained demand and the strength of multiple growth drivers, while reaffirming its adjusted earnings per share (EPS) guidance within the prior range of $2.95 to $3.05.
• The transcatheter aortic valve replacement (TAVR) segment generated $1.3 billion in sales, increasing 10.5% year-over-year and benefiting from procedural growth, market expansion through new clinical evidence, and the exit of a major competitor in the prior-year quarter.

• Oura, Inc. plans to sell 50.0 million shares at an expected price of $40.00 to $44.00 per share and list on the Nasdaq Global Select Market under the ticker OURA.
• At the $42.00 midpoint, the offering would raise approximately $2.10 billion and value the company at approximately $13.48 billion.
• Goldman Sachs, Morgan Stanley and J.P. Morgan are leading the offering. 

• ADARx Pharmaceuticals presents a high-quality, late-stage biotechnology offering supported by a diversified siRNA platform, a Phase 3 lead program, approximately $427 million of existing cash and investments, and substantial strategic validation from AbbVie.
• The transaction is being led by J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital, providing a strong healthcare-focused underwriting syndicate with broad institutional distribution.
• AbbVie’s planned investment of up to $100 million in a concurrent private placement adds credibility to both the platform and valuation.

• On September 11, 2026, Biodexa Pharmaceuticals, PLC (BDRX) announced interim results for the first half of 2026 and provided a business update.
• The company is continuing to enroll patients in the registrational SERENTA Phase 3 clinical trial of MTX230 (eRapa) in familial adenomatous polyposis (FAP).
• Thus far, 92 of an expected 168 patients have been enrolled in the study.

• The Ensign Group, Inc. reported financial and operational results for the second quarter of 2026 that reflected continued growth and strong clinical performance across its portfolio.
• The company focuses on post-acute care through a unique integrated clinical model called ONE CLINICAL, which emphasizes collaboration between nursing and therapy disciplines, aiming to improve outcomes such as rehospitalization rates, emergency department visits, and CMS quality ratings.
• Financially, Ensign achieved GAAP diluted earnings per share of $1.68, a 16.7% increase year-over-year, while adjusted earnings per share rose 20.8% to $1.92.

• Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s health, and organ health.
• The company processed a record 1,044,000 tests during the quarter, with clinical Minimal Residual Disease (MRD) oncology tests increasing approximately 56% year-over-year to 283,000 units, including the largest sequential increase recorded at 34,000 units above the prior quarter.
• These volumes contributed to approximately $753 million in revenue, representing a 38% increase compared to Q2 2025, or 40% excluding revenue true-ups.

• Repligen reported its financial and operational results for the second quarter of 2026, demonstrating continued growth and strategic progress amid a complex bioprocessing market environment.
• The company achieved $204 million in revenue, reflecting 12% reported growth and 13% organic growth year-over-year, driven primarily by strong recurring revenues across multiple product franchises.
• Proteins led the growth with approximately 50% expansion, supported by contributions from OEM partnerships and growth factor demand.

• ADARx Pharmaceuticals, Inc. (ADRX) is preparing to sell 21.875 million shares of common stock on the Nasdaq Global Select Market at an expected price of $15.00 to $17.00 per share.
• At the $16.00 midpoint, the offering would raise $350.0 million and value the company at approximately $1.64 billion.
• J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital are serving as underwriters.

• SKY-515 came out with 15-month interim data recently.
• What was said in the press release was unsurprising in light of the 12-month data shared.
• At 12 months, participants receiving SKY-0515 demonstrated favorable outcomes across every component of the composite Unified Huntington’s Disease Rating Scale (cUHDRS): Total Functional Capacity (TFC): Mean change from baseline of +0.

• On Tuesday, Meera Kapoor wrote about how GLP-1 drugs cause people’s skin to become saggy – the effect that’s now popularly known as “Ozempic face”.
• Two solutions are botulinum neurotoxin (“Botox”) and dermal fillers.
• Botox is injected into the skin to reduce wrinkles. Such wrinkles include frown lines, forehead lines and so-called “crow’s feet.

• Won Tech’s exports increased by 59.8% YoY in 2025 and by 21.5% YoY in 1H 2026. The company’s export sales to the U.S. increased sharply in 1H 2026. 
• Won Tech is currently trading at P/E of 9.8x and P/B of 2.2x based on 2026 consensus earnings estimates (50% to 60% discount to its historical valuation multiples). 
• Won Tech provides medical aesthetics and surgical devices. The company’s products specializes in the laser and energy based medical solutions used for skin rejuvenation and face lifting procedures. 

• Oura brings a compelling mix of 74% revenue growth, 5.0 million paid members, strong retention and recurring subscription revenue to the IPO market.
• Cornerstone interest from Eli Lilly and Dragoneer adds another notable dimension to an offering targeting a valuation above $14 billion.
• With Oura serving as the first major technology IPO test after Labor Day, investor demand and pricing will be closely watched.

• This week, Corteva and Vylor hosted their respective analyst days.
• Corteva also set the distribution ratio (1:1) for the spin-off, announced a ticker (VYLR), and confirmed expected regular way trading (10/1/2026).
• Meanwhile, Medtronic announced it would distribute its ~90% stake in its diabetes business, MiniMed (MMED), through an exchange offer (MDT shareholders get to decide which stock they want to own).

• ADARx targets a $1.5–$1.7 billion valuation with a $15–$17 IPO range and 21.875 million shares offered.
• AbbVie’s up to $100 million concurrent investment provides a strategic validation point alongside ADARx’s late-stage siRNA pipeline.
• Proceeds will fund multiple clinical programs, led by Phase 3 onvuzosiran and Phase 2 agazisiran development.

• The Stagnation of the Generic Core: Zhejiang Jingxin’s core business is locked in structural stagnation, with total revenue dipping 2.14% in 2025 to RMB 4.07 billion and continuing to slide 1.46% to RMB 1.987 billion in 1H2026. The pressure from Volume-Based Procurement (VBP) is relentless, with 38 to 40 of the company’s products now swept into national or regional procurement lists, rendering the generic and API segments a declining-margin volume game.
• Dimdazenil’s Growth versus Competitive Headwinds: While the Class 1 innovative insomnia drug Dimdazenil (Jingnuoning®) achieved strong growth—surging to RMB 195 million in 2025 and hitting RMB 153 million in 1H2026—its long-term commercial peak is highly contested. The drug currently holds a 5.4% market share, but it faces severe encroachment from newly approved dual orexin receptor antagonists (DORAs), notably Eisai’s Lemborexant and Idorsia’s Daridorexant, which do not carry the clinical psychiatric stigma of GABA-targeting compounds.
• Strategic Capital Underfunding: A deep contradiction exists in the company’s capital allocation. While the company executed a massive RMB 609 million share buyback in 2025 (retiring 5.49% of outstanding shares), it simultaneously starved its future pipeline by cutting R&D expenses to RMB 368 million in 2025 (a 9.0% intensity rate) and down to just 8.3% of revenue in 1H2026. The aggressive pursuit of a dual A+H listing in Hong Kong, with the updated prospectus filed on September 18, 2026, is a direct attempt to secure non-dilutive offshore capital to fund clinical trials and late-stage licensing deals that the domestic cash flow can no longer comfortably support.

• CooperCompanies reported third-quarter fiscal 2026 consolidated revenue of $1.066 billion, up 1% year-over-year on both reported and organic bases.
• CooperVision generated $717 million of revenue, essentially flat from a year earlier, while CooperSurgical increased 3% organically to $349 million.
• CooperVision was affected by deliberate reductions in U.S. channel inventory, which are expected to continue weighing on fourth-quarter results.

• Nu-3 is a modified nucleotide (Bisphosphocin), not a peptide. This is a critical structural distinction that gives it a massive advantage over antimicrobial peptides (AMPs) by avoiding proteolytic degradation in the active wound bed, while maintaining a straightforward, low-cost organic synthesis profile with manageable COGS.
• The company’s capital position is extremely precarious. With only $2,584,774 in cash and $2,000,000 in short-term investments as of June 30, 2026, the runway only extends into Q1 2027. This barely covers the newly initiated Phase 2a trial for infected diabetic foot ulcers (iDFU), making a highly dilutive capital raise or an unfavorable licensing deal almost inevitable before topline data is generated.
• The commercial viability of the AMR sector remains fundamentally broken. Despite the clinical promise of Nu-3’s physical membrane-disrupting mechanism, the lack of passage of the PASTEUR Act leaves the market reliant on volume-driven models. This forces new antimicrobials to compete against cheap generic antibiotics, severely limiting the near-term commercial valuation of the asset.

• The failure of MapLight’s once-daily (QD) dosing regimen for ML-007C-MA in the Phase 2 ZEPHYR trial is a severe commercial blow. By failing to achieve statistical significance on the primary PANSS endpoint with the QD formulation, MapLight has lost its key point of differentiation against Bristol Myers Squibb’s twice-daily (BID) Cobenfy, forcing MapLight to advance its own BID regimen (210/3 mg BID) into Phase 3.
• Despite an inferior cross-trial efficacy profile compared to Cobenfy, ML-007C-MA retains real-world adherence advantages. While its -4.5 point drug-placebo PANSS difference and 0.37 effect size are weaker than Cobenfy’s -8.4 to -9.6 points, ML-007C-MA has a simple one-dose titration and no fasting requirements. This directly contrasts with Cobenfy, which requires a complex multi-week titration and must be taken on an empty stomach to avoid a 90% drop in trospium absorption that triggers severe gastrointestinal side effects.
• MapLight’s $501.3 million cash position is sufficient to reach Phase 3 readouts but necessitates complete pipeline stagnation. To preserve its runway through 2028 and fund the Phase 3 ZEPHYR-2 trial in schizophrenia and the Phase 2 VISTA trial in Alzheimer’s disease psychosis (ADP), MapLight has been forced to pause all preclinical and discovery-stage programs, including its pre-clinical QD candidate ML-055. Self-launching is highly unviable, making an eventual out-licensing deal or strategic acquisition by a large pharmaceutical player the only logical end-game.

• Zhejiang Jingxin Pharmaceutical is a group focused on CNS, cardiovascular, and cerebrovascular diseases, generating revenue from drugs, APIs, medical equipment, seeking a primary HKEX listing.
• Sole approved innovative drug, Dimdazenil, launched in 2024 for insomnia. Operates eleven manufacturing facilities, with largest customer accounting for 17.2% of revenue.
• Revenue was RMB4,069,361 and profit RMB771,731 in 2025. Profit for the period decreased by 10.0% to RMB358.0 million (six months ended June 30, 2026).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Junshi Biosciences (1877 HK) reported stellar performance for 1H26, with the company reporting its maiden net profit. Steady revenue growth of toripalimab led to breakthroughs in revenue and profit.
• Tuoyi is reporting increasing revenue in China, driven by continued expansion of indications and NRDL coverage. 2Q26 represents 11th consecutive quarter of sequential revenue increase for Tuoyi.
• Continued clinical advancement of core pipelines, including bispecific antibody candidate, JS207 and ADC candidate, JS212 with strong clinical trial data for various types of solid tumors enhance visibility beyond toripalimab.  

• IDEXX Laboratories has moved deeper into veterinary artificial intelligence with its September 16, 2026 acquisition of CoVetAI, an AI-native clinical workflow platform designed to automate documentation, organize patient information, and streamline communication across veterinary practices.
• Financial terms were not disclosed, but the strategic logic extends beyond simply adding an ambient scribe product.
• CoVetAI will be integrated into IDEXX’s broader software, diagnostics, and AI ecosystem while continuing to support non-IDEXX practice management systems and third-party integrations.

• Dominant Regional Medical Network: Docquity has established a verified digital community of healthcare professionals across Southeast Asia and the Middle East, scaling to over 500,000 users. By providing essential continuing medical education and peer collaboration tools, the platform has secured a highly engaged digital community of healthcare professionals across Southeast Asia, North Asia and the Middle East, scaling to over 500,000 users.
• Enterprise Monetisation Engine: The core investment case rests on the company’s transition from a pure networking utility to an artificial intelligence-driven intelligence layer for life sciences companies. By monetising physician engagement signals through its data and insights offering, formalised in January 2026 as the Docquity Engage™ intelligence engine, Docquity captures recurring revenue from multinational pharmaceutical clients, having grown operating revenue by 29.7% year-on-year to US$5.2m in FY24.
• Escalating Financial Losses: The company remains loss-making at the operating level and reported a pre-tax loss of US$61.1m in FY24, although this figure is dominated by non-cash revaluations of preference shares classified as debt. The same revaluations lifted total liabilities to US$96.6m, while cash more than halved during FY24 as operations continued to consume funds, leaving the business reliant on further external capital

• MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. This prospectus registers shares for resale by selling stockholders, with no proceeds for the company.
• MapLight Therapeutics has lead candidate ML-007C-MA for schizophrenia and ADP, with Fast Track designation and positive Phase 2 results. ML-004 for ASD also had topline Phase 2 results.
• The company has incurred substantial losses since inception and anticipates increasing losses, potentially never achieving or maintaining profitability in the future.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Ultragenyx Pharmaceutical suddenly has a new story for Wall Street.
• Shares closed 13% higher at $14.50 after the FDA approved Fayuvi, a one-time gene therapy for pediatric patients with Sanfilippo syndrome Type A, a rare inherited disorder that progressively damages the brain and nervous system.
• The approval is notable because families previously had no FDA-approved treatment designed to address the underlying cause of the disease.

• Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company developing novel antimicrobials for infectious diseases, especially antibiotic-resistant strains. The company will not receive proceeds from this prospectus’s share resale.
• Lakewood-Amedex has 74 issued and 27 pending patent applications as of August 2026, with lead product Nu-3 advancing to Phase 2a clinical study.
• As of December 31, 2025, the company reported an accumulated deficit of $53.4 million. The auditor expressed substantial doubt about its going concern ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• MVA Platform Commercial Feasibility: While Modified Vaccinia Ankara (MVA) viral vectors offer superior thermal stability and robust T-cell immunity compared to mRNA, their commercial viability is severely constrained by complex cell-based manufacturing economics and the entrenched global monopoly of Bavarian Nordic’s Jynneos (marketed as Imvanex or Imvamune), which commands a price of approximately $100 per dose.
• Extreme Capital Constraints: GeoVax is operating on a microscopic cash balance of $3,143,422 as of June 30, 2026, which provides a runway extending only into October 2026. To survive, the company is entirely dependent on shareholder approval at the October 27, 2026 special meeting to authorize a highly dilutive 11,395,256-share warrant exercise at $0.64 per share to raise $7.29 million gross, alongside a reverse stock split between 1-for-10 and 1-for-25 to avoid Nasdaq delisting.
• High-Risk Phase 3 Pivot: Following the devastating April 11, 2025 BARDA “Stop Work Order” and subsequent termination of the $45 million GEO-CM04S1 COVID-19 program, GeoVax has completely pivoted to the 500-participant GEO-MVA-301 Phase 3 immunobridging trial for mpox and smallpox. Despite operational progress, including a September 14, 2026 agreement with the CEPI Centralised Laboratory Network, executing this trial under current capital constraints and listing deficiencies remains a highly precarious proposition.

• Commercial Viability and Clinical Gaps: The ZSmile platform offers a compelling lifestyle value proposition by eliminating 22-hour daily wear and daytime speech/eating interference, but it faces significant clinical finishing limitations. In approximately 5.00% of cases, patients still require conventional braces to be bonded for 4 to 6 weeks for final precision finishing, which creates resistance among premium-focused orthodontists.
• Extreme Financial Precarity: Dror’s financial position is critical. As of June 30, 2026, the company had total assets of just $258,936, a negative working capital of $(3.75) million, and an accumulated deficit of $23.32 million. The August 2026 capital raise of $275,000 via 0% interest convertible debentures is a short-term stopgap maturing on October 19, 2026, which underscores its high restructuring risk.
• Go-to-Market Hurdles: While a 2,000-to-1 reverse stock split is planned for a Nasdaq uplisting, the commercial launch cannot scale without a major strategic partner. High customer acquisition costs (CAC) and the dominance of Align Technology—which shipped 2.61 million cases in FY2025 and maintained a clear aligner average selling price (ASP) of $1,260 in Q2 2026—mean Dror’s technology is more likely to be acquired for its IP portfolio rather than successfully launched independently.

• GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
• GEO-MVA Phase 3 clinical trial initiation is planned for Q4 2026, and Gedeptin® Phase 1/2 trial for advanced head and neck cancers completed.
• As of June 30, 2026, cash and cash equivalents were $3,143,422, sufficient to fund operations into October 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Severe Financial Distress: NuvOx is operating in extreme financial distress, holding just $332,000 in cash against a staggering $32.11 million in total liabilities as of June 30, 2026. Its pending $20.02 million IPO on the NYSE American is a literal survival mechanism to address its going-concern risk rather than a standard growth-capital raise.
• Clinical Validation is the Key Gate: The phase-transition mechanism of NanO2 (dodecafluoropentane, or DDFP) allows it to be active at less than 1/200th of the dose of historical perfluorocarbons (PFCs), bypassing the severe reticuloendothelial system (RES) toxicity and thrombocytopenia that terminated earlier trials like Alliance’s Oxygent. However, the core clinical challenge is overcoming deep-seated physician skepticism regarding the risk of microvascular gas emboli during liquid-to-gas transition in vivo.
• Strategic Pivots are Hard but Rational: The company’s decision to shelf its sickle cell program (NVX-508) and focus entirely on the glioblastoma multiforme (GBM) RESTORE trial is highly rational. GBM has an unchanged standard of care (the Stupp protocol) since 2005, making neuro-oncologists highly receptive to radiosensitizers that can reverse tumor hypoxia. Conversely, sickle cell requires large, expensive cardiovascular safety trials and faces a crowded field of newly approved gene therapies, which NuvOx simply cannot afford.

• Medtronic (MDT) announced an exchange offer on September 14, 2026 whereby investors can exchange their MDT shares for shares of MiniMed (MMED), Medtronic’s diabetes spin-off.

• To incentivize the exchange, MDT investors will receive $107.53 of value in MMED shares for every $100 of value in MDT shares.

• I expect the exchange offer to be oversubscribed.

• Tender Offer Alignment: The $230 million modified Dutch auction tender offer (priced at $5.00 to $5.75 per share, expiring September 29, 2026) is structurally engineered to distribute the non-contingent proceeds of the Moderna settlement ($178.4 million received directly in July 2026) and the anticipated Q3 2026 Genevant parent dividend. This returns the windfall directly to shareholders, keeping the clinical-stage HBV asset (imdusiran) as a free option funded by the company’s existing $92.6 million baseline cash reserves.
• High Tax Friction on Genevant Dividend: While Arbutus owns a 16% equity stake in Genevant, extracting cash via a Genevant dividend involves severe tax friction. Under the Canada-Switzerland Income Tax Convention, the standard Swiss withholding tax on dividends is reduced from 35% to 5% for corporate holdings over 10%, but the mechanics require a notification and refund filing process that creates structural cash-flow lags and complex transfer-pricing audits.
• LNP Portfolio Prison: Arbutus cannot execute a clean spin-off or sale of its remaining Lipid Nanoparticle (LNP) patent portfolio. Under the 2018 Cross-License Agreement, Arbutus granted Genevant an exclusive, perpetual, worldwide license to the LNP patents for all non-HBV applications. This structural arrangement permanently ties the IP to the Genevant JV, meaning any potential buyer would acquire a portfolio that has already been fully hollowed out of its commercial applications outside of hepatitis B.

• SFC Suspension Driven by pre-IPO Put Options: The SFC’s rare Section 8(1) trading suspension on September 10, 2026, stems from suspected “rigging” of the July 2025 IPO. Pre-IPO Series B and B-1 agreements contained a standard put option allowing investors to retrieve their capital with compounded interest if the company failed to list by a certain deadline. This created an existential, systemic incentive for management to force the listing through, despite an incredibly weak international book (only 0.89 times subscribed), resulting in suspected artificial book-building.
• Severely Impaired Asset Valuations and “Regulatory Distress Discounts”: While CBT-001 for pterygium remains a scientifically compelling asset (12-month Phase 3 primary endpoints completed in June 2026, with top-line data imminent), its valuation is now structurally crippled. Out-licensing open geographies like the US and Europe to secure non-dilutive capital is the company’s only survival path. However, any potential big pharma or large biotech counterparties hold all the leverage and will demand a severe distress discount, likely slashing upfront cash expectations from US$20 million down to a fire-sale US$5 million.
• Extreme Runway Crisis & Operational Collapse: As of June 30, 2026, Cloudbreak possessed only US$32.7 million in cash and cash equivalents. Against a monthly operational cash burn of US$5.0 million to US$6.0 million (driven by ongoing Phase 3 clinical developments and climbing G&A expenses), the company’s remaining runway is less than 4 to 5 months (extending only into early 2027). Because the trading suspension blocks equity capital markets, and banks are highly likely to freeze their US$66.4 million unutilised credit facilities due to the active SFC probe, the company is facing an imminent liquidity wall.

• Dror Ortho-Design, Inc. is a medical device company developing ZSmile, an AI-based platform for discreet, less painful smile correction using a single smart aligner.
• ZSmile Platform received FDA 510(k) clearance in February 2026, targeting a $17 billion addressable market within the growing clear aligners sector.
• Auditor expressed substantial doubt about going concern; company reported $94,000 cash and $3.8 million working capital deficit as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Electra priced an upsized 23.33 million shares at $15.00, but opened flat and closed at $13.25, down 11.7% on persistent selling pressure.
• The more-than-four-times oversubscribed book failed to translate into aftermarket support, highlighting a disconnect between headline demand and committed demand.
• Electra’s earlier-stage development profile and distant clinical milestones may have contributed to limited investor patience despite a constructive recent biotech IPO backdrop.

• Nephrocare Health Services (NEPHROPL IN), which operates under the NephroPlus brand, has built a network of 550 dialysis clinics across 357 cities and five countries.  
• International operations now contribute about 45% of revenue, compared with roughly 30% around 18 months earlier. Higher overseas realisations are lifting revenue per treatment and margins.
• The moat is not the dialysis machine. It is the operating layer around it: procurement scale, trained manpower, an in-house biomedical team, payer relationships, clinical protocols and technology.

• Alignment Healthcare, Inc. (NASDAQ: ALHC) is a high-growth, tech-enabled Medicare Advantage (MA) organization that has demonstrated exceptional top-line expansion, scaling annual revenue from $1.82B in FY2023 to $3.95B in FY2025 (a 3-year CAGR of 40.16%) through superior clinical engagement, strong member retention, and strategic market share gains.
• The enterprise has reached a pivotal operational inflection point, transitioning from historic net losses to GAAP net profitability and robust positive cash flow generation, delivering $139.93M in operating cash flow and $113.15M in free cash flow in FY2025, followed by accelerating profitability in 1H 2026 ($47.98M combined net income across Q1-Q2 2026).
• Anchored by its proprietary Alignment’s Virtual Assistant (AVA) clinical intelligence platform and consistent 4.0+ CMS Star Ratings, ALHC maintains a durable competitive moat in clinical cost management and risk stratification, positioning it to disproportionately capture market share as legacy national competitors retrench amid CMS regulatory adjustments.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• NuvOx Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oxygen therapeutic solutions for diseases where hypoxia plays a critical role.
• NanO2 is in clinical development for stroke, GBM, and ARDS, with orphan drug designation for GBM and sickle cell anemia.
• Total assets were $1,955 and cash was $332 as of June 30, 2026. Total liabilities were $32,106.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Cloudbreak Pharma (2592 HK), a clinical-stage eye-disease drug developer, was listed on the HKEx on the 3rd July 2025 at HK$10.10/share, and promptly fell 39% on debut.
• The downward trend continued. Shares were suspended by the SFC on the 10th September 2026, with a last trading price of HK$1.19/share, down 88.2% from IPO. 
• The SFC said it has “serious concerns” that Cloudbreak’s 2025 IPO “may have been rigged to create an artificial impression of demand” for its shares.

• Median discount tightened from -1.1% to -0.5%, but the mean widened to -3.7%, as several already-large discounts moved further away from parity.
• Carlsberg was the largest widener at -18.8%, while Grifols reached -33.3% and MFE -28.3%, improving prospective returns from convergence trades.
• Grifols and MFE stand out among new positions, while Ericsson’s B-only SEK15bn buyback remains the most relevant active capital-structure development.

• Simplifying the dual-class share structure (Class A to Class B discount) is legally and structurally locked. Under Spanish corporate law, any unification requires separate majority approvals from both Class A and Class B shareholders. Because the founding family holds their controlling 30%+ stake entirely in Class A shares, they will not vote to unify the classes without a premium or conversion ratio that heavily favors Class A, meaning a 1:1 conversion remains highly improbable.
• Free cash flow conversion remains constrained by structural related-party friction, despite improved governance. Although the appointment of Nacho Abia as CEO and Rahul Srinivasan as CFO has professionalized the C-suite, the underlying assets leased from Scranton Enterprises (such as the headquarters and plasma centers owned by Haema and BPC) continue to siphon cash through complex lease obligations and legacy cash-pooling agreements.
• Grifols continues to lag behind CSL in plasma collection yield and cost efficiency. Grifols’ Cost Per Liter (CPL) remains structurally higher than CSL’s, driven by a slower rollout of next-generation plasmapheresis technology (like Terumo’s Rika system) and a higher historical reliance on high-cost US donors, though the joint venture in Egypt is a mid-term attempt to diversify this cost base.

• Arbutus Biopharma’s $230m tender offer for 20%-23% of shares is priced between $5.00-$5.75/share, expiring September 29.
• The tender is funded by a $178m settlement from Moderna, with additional cash reserves of $93m as of June.
• Arbutus’s value is primarily in lipid nanoparticle patents, with potential $1.3bn contingent payment from Moderna and ongoing litigation with Pfizer/BioNTech.

• Clinical Best-in-Class Potential: Onvuzosiran (ADX-324) demonstrates superior durability over late-stage competitor donidalorsen, with its 300 mg dose maintaining ≥80% plasma kallikrein (PKK) suppression through Day 169, making a twice-yearly (Q6M) or quarterly (Q3M) dosing regimen highly viable for hereditary angioedema (HAE) prophylaxis.
• IPO to Fund Capital-Intensive Pipeline: Despite entering 2026 with $427.3 million in cash, ADARx’s cash burn is accelerating rapidly. First-half 2026 R&D expenses jumped 61% year-over-year to $48.3 million, driven by the Phase 3 STOP-HAE trial and multiple Phase 2 trials for agazisiran, making the September 2026 IPO filing a necessary step to secure its runway through key late-2027 readouts.
• Extrahepatic Delivery as the Ultimate Valuation Unlock: While the AbbVie partnership validates ADARx’s liver-targeted platform, the true structural re-rating of the company hinges on its upcoming 2027 clinical entries for extrahepatic assets, particularly ADX-199 for Alzheimer’s disease (CNS-targeted).

• Severe Revenue Contraction Driven by Pricing Commodore: Veri MedTech’s flagship platform, Veriheal, experienced a severe 34.3% year-over-year revenue decline from $17 million in 2024 to $11 million in 2025. This contraction was driven by its premium pricing model ($199 for new patients, $149 for renewals) in an increasingly commoditized market where direct competitors like NuggMD and Leafwell have anchored pricing at $99.
• The “Infinite Wellness Loop” is a Valuation Narrative, Not an Operational Reality: The company’s strategic expansion into direct-to-consumer wellness via DosePop is heavily constrained by prohibitive customer acquisition costs (CAC). The cross-sell conversion rate of medical cannabis patients from Veriheal to DosePop is under 2%, failing to validate the executive team’s claims of a self-reinforcing, zero-marginal-CAC retention engine.
• NASDAQ Uplisting is an Absolute Going-Concern Survival Trigger: With a working-capital deficit of $2.05 million and a shareholders’ deficit of $2.35 million as of late 2025, Veri MedTech’s upcoming $15 million NASDAQ uplisting (fixed at $4.00 per share as of September 14, 2026) is a critical liquidity event. Failure to execute this transaction within the next quarter will likely lead to technical default and potential insolvency.

• Eco Animal Health announces that the US Department of Agriculture, Centre for Veterinary Biologics (USDA-CVB) has confirmed that Eco Animal Health’s US field safety trial data for its proprietary poultry vaccine, ECOVAXXIN®MS, fulfils the requirement to enable licensing of the product.
• This represents a major regulatory milestone in the path towards commercial deployment.
• The Group expects to receive US marketing approval by the end of CY26.

• Jcr Pharmaceuticals (4552 JP) revenue increased 13% to ¥9.7B in Q1FY27, mainly driven by Izcargo and contractual payments, marred to an extent by NHI price revision impact on Growject.
• Company reiterated FY27 guidance, expects revenue to be ¥45.7B (+13% YoY). Operating income expected to be ¥1.1B (up 98%) and net income ¥200M, down YoY.
• With no near-term robust incremental revenue visibility, nor any significant approvals pending the downside potential for the stock remains strong.

• Transition to Operational Profitability: Syra Health recorded $491,221 in net income for the six months ended June 30, 2026, representing its first sustained pivot to profitability. However, despite positive operating cash flow of $643,183, liquidity remains a serious headwind, with management’s independent auditor continuing to flag a going-concern warning.
• Concentration and Procurement Realities: High revenue concentration—with Humana and the Indiana Family and Social Services Administration (FSSA) historically dominating the receivables ledger—presents an existential risk. State-level procurement cycles spanning 12 to 24 months create structural revenue volatility and prolong Days Sales Outstanding (DSO) on government receivables.
• Digital Health Monetization Demystified: While the Syrenity mental health application has potential under the recently announced CMS ACCESS Model partnership with HealthSync, commercial B2B monetization is still in its infancy. True scalability is limited by high-friction government implementation cycles rather than frictionless, high-margin SaaS expansion.

• Only 0.366m shares beyond Rossini’s committed stake have been tendered, despite the offer ending on 15 October. Minority participation at €51.29 remains negligible.
• CVC/GBL could reach 56.79% after physical settlement of the TRS, leaving them needing only 22.87% of remaining shares to secure two-thirds control.
• We assign a 65% probability to an increased offer and derive a probability-weighted value of €55.07/share, 4.6% above the 15 September close.

• Electra is developing precision immunotherapies designed to selectively eliminate disease-driving immune cells while preserving normal immune function.
• Ipsoprubart has generated encouraging early data in malignancy-associated HLH, including 100% overall survival and overall response in 12 frontline patients.
• Sector momentum and current demand are constructive, with all four August biotech IPOs trading above issue prices and Electra’s book reportedly oversubscribed.

• Our 2021 demographic and capacity-growth thesis largely worked, but property-led expansion introduced multi-year lags between capital deployment, occupancy maturation and earnings.
• FY03/2026 headline ROIC is roughly 6.8%; removing property revaluation noise lifts it to 8.1%, while occupancy normalization suggests roughly 9–10%.
• That narrows our original forecasting error but does not erase it: even seasoned-capital returns around 10–11% remain below our former 20% hurdle.

• Electra Therapeutics is a late clinical-stage biopharmaceutical company pioneering precision medicines for immune-mediated diseases and cancer, targeting SIRP to deplete disease-driving cells.
• Ipsoprubart received Breakthrough Therapy designation from FDA and PRIority MEdicine from EMA for sHLH, with ELA822 Phase 1 initiated.
• The independent auditor’s report included a ‘going concern’ explanatory paragraph, and no revenue has been generated to date.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Johnson & Johnson could be preparing to unwind one of the biggest healthcare bets in its history.
• Apollo Global Management is reportedly in talks over a possible acquisition of all or part of J&J’s DePuy Synthes orthopaedics business at a valuation close to $20 billion, roughly 14 years after J&J paid $21 billion for Synthes and combined it with DePuy to build a global orthopedics powerhouse.
• On the surface, the numbers make the transaction look like an expensive round trip.

• MiniMed (MMED) Split-Off Mechanics and EPS Impact: The voluntary exchange offer launched on September 14, 2026, to divest Medtronic’s remaining 89.86% stake in MiniMed Group at a 7% discount functions as a tax-free split-off. This transaction shrinks Medtronic’s outstanding share count without draining balance sheet cash, effectively acting as a highly accretive share buyback that lifts adjusted EPS while removing a lower-margin, high-R&D business.
• Regulatory Inflation and QMSR/EU MDR Compliance Friction: The transition to the FDA’s new Quality Management System Regulation (QMSR) on February 2, 2026, alongside ongoing EU MDR requirements, has permanently elevated the baseline for operational quality and compliance costs. This structural regulatory inflation drives administrative overhead—contributing to a 14% rise in adjusted SG&A in Q1 FY27—and lengthens product registration cycles, neutralizing some gross margin gains from corporate efficiency programs.
• Cardiovascular and CAS Ramps Disguise Underlying Organic Growth Trajectory: Medtronic’s blockbuster Q1 FY27 results (13.7% organic revenue growth to $9.756 billion) were heavily inflated by a 53rd fiscal week, which contributed $570 million or 670 basis points of growth. Stripping out this extra week and the explosive, early-stage ramp of the Cardiac Ablation Solutions (CAS) segment (+88% global organic growth driven by the Affera and Sphere-9 launches), the core product portfolio’s organic growth remains in the mid-single digits, reflecting the long-term productivity challenges of Medtronic’s $2.9 billion annual R&D engine.

• Neuren Pharmaceuticals (NEU AU)‘s Daybue reported 2Q26 revenue of $125M, up 30% YoY and 24% QoQ, which is the highest quarterly sales since launch, mainly driven by volume.  
• Neuren has raised anticipated royalties for the full year 2026 to a range of $53M to $56M (up 24–33% YoY) from the previous range of $50M to $54M.
• Neuren’s investigational drug candidate, NNZ-2591 progressed to Phase 3 trial in Phelan-McDermid syndrome, which has a larger addressable patient population than Rett syndrome.

• The CVC-GBL “Delisting Merger” provides an absolute mechanical bottleneck for minority holdouts. If private equity sponsors fail to reach the 90% squeeze-out threshold under the March 2026 capital markets reform, they can execute a merger of Recordati with the unlisted Respighi BidCo S.p.A. with a two-thirds (66.7%) voting majority. Under Article 2437-quinquies of the Italian Civil Code, dissenting shareholders exercising their withdrawal right (diritto di recesso) will have their shares valued at the 6-month arithmetic average closing price, which is structurally anchored close to the €51.29 offer price, neutralizing activist demands for €60.00.
• Management is heavily incentivized to support the sponsors over public minorities through equity-acceleration clauses rather than direct M&A fees. Under the 2023–2025 and newly implemented 2026–2028 Performance Share Plans, a change of control triggers the immediate vesting and cash-out of all unvested awards. Since Key Management Personnel have target short-term incentives capped at 90% of their base salary and are explicitly barred from transaction-specific bonuses, their financial windfalls are tied entirely to facilitating the successful execution and exit of the sponsors’ private structure.
• The commercial viability of Recordati’s high-margin rare disease portfolio is increasingly exposed to regulatory and supply chain vulnerabilities. The peak sales target for Isturisa (upgraded to greater than €1.2 billion) and the expansion of Enjaymo (which posted €91.0 million in H1 2026) depend on highly centralized, single-source API manufacturing networks. Furthermore, these products face direct pricing pressure under the US Inflation Reduction Act (IRA) and increasingly stringent Health Technology Assessment (HTA) re-evaluations across major European markets, which threaten the 38.3% H1 2026 EBITDA margins.

• Syra Health Corp. is a healthcare services company focused on preventative health, holistic wellness, health education, and equitable healthcare.
• Syra Health reported total revenues of $4.7 million for the six months ended June 30, 2026, and launched Syrenity in Q4 2024.
• Auditors expressed substantial doubt about the company’s ability to continue as a going concern for 2025 and 2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Veracyte is expanding its position in cancer diagnostics through an agreement to acquire Convergent Genomics for $150 million upfront, with up to another $30 million tied to reimbursement milestones for UroAmp MRD.
• The transaction would add a urine-based molecular residual disease test designed to detect, monitor, and assess recurrence risk in urothelial cancer, initially validated in non-muscle invasive bladder cancer.
• The timing is notable because Veracyte has already been building a broader bladder cancer franchise around Decipher Bladder and its recently launched TrueMRD platform for muscle-invasive bladder cancer.

• Medtronic’s exchange offer allows shareholders to swap MDT shares for MMED shares at a 7.53% premium, expiring October 9.
• Hedging is challenging due to limited borrow availability and high fees, with unhedged positions exposed to volatility risks.
• Odd-lot holders are prioritized in the tender, avoiding proration, while oversubscription is likely, affecting larger positions.

• ✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality & Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company developing precision medicines that selectively deplete disease-driving immune cells through the signal regulatory protein family.
• Its lead candidate, ipsoprubart, is a first-in-class pan-SIRP antibody designed to target pathological myeloid and T cells while preserving unaffected immune populations.
• Ipsoprubart is being evaluated as a frontline treatment for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with high mortality and limited treatment options.

• Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an expected price of $14.00 to $16.00 per share.
• At the $15.00 midpoint, the offering would raise approximately $325.0 million and value the clinical-stage biotechnology company at roughly $916.5 million.
• Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers. The shares are expected to begin trading on Friday, September 18, 2026.

• Actinium Pharmaceuticals is a biology-driven radiotherapy company advancing candidates in oncology and conditioning for solid tumors and hematological malignancies.
• Its approach is expanding the reach of radiopharmaceuticals to novel target-isotope combinations in acute myeloid leukemia, solid tumors & conditioning.
• It favors Ac-225 isotopes in its oncology pipeline and I-131 for conditioning candidates.

• Medtronic plc reported a robust start to fiscal year 2027 with first-quarter revenue reaching $9.8 billion, reflecting a 13.7% organic growth rate and adjusted earnings per share (EPS) of $1.45, both surpassing consensus expectations.
• This growth was broad-based across multiple business segments, geographic regions, and product lines, supported by an additional selling week contributing approximately $570 million to revenue.
• The company emphasized strength in its three largest operating units: Cardiac Rhythm Management (CRM), Cranial & Spinal Technologies (CST), and Surgical, which all posted solid results.

• Pharma-Bio Serv(PBSV) Company Sponsored Research Report

• Pharma-Bio Serv(PBSV) Company Sponsored Research Report

• Prodia Widyahusada (PRDA IJ) is Indonesia’s reading diagnostic company, with around a 35% market share and a network of 392 outlets across the archipelago.
• PRDA booked +8.5% sales growth in 1H2026, with improving margins, as it shifted toward more esoteric testing. Testing volumes were driven by external referrals, doctors’ referrals, and corporate customers. 
• The company’s digital sales through U by Prodia saw strong growth, with Prodia for Doctors also seeing increasing traction, but with lower capex. Valuations are attractive versus Indian comparables.

• HealthEquity, Inc. reported its second quarter fiscal 2027 financial results highlighting continued growth and profitability amid an evolving healthcare affordability landscape.
• The company delivered accelerated revenue growth, achieving an 8% year-over-year increase, supported by expanding Health Savings Account (HSA) metrics.
• Total HSA assets increased 14% and accounts grew 8%, with new sales rising 24% year-over-year—the strongest quarterly new account addition outside of the typical open enrollment period.

• Infinitt Healthcare (071200 KS) announced a major dividend program of providing 65.4 billion won in dividends to shareholders from 3Q 2026 to 2Q 2027.
• Given the company’s current market cap of 276 billion won, the dividend amount of 65.4 billion won represents 24% of its market cap.
• The company has a strong balance sheet. Net cash was 212 billion won at the end of 2Q 2026, representing 79% of market cap.

• Zentek’s core asset is the Albany Graphite Project, a PEA-stage deposit of naturally occurring ultra-high-purity graphite in northern Ontario.
• Albany is being developed to supply 5N (99.999%) specification-grade graphite to the nuclear, defence, and semiconductor markets, and its recent PEA carries an after-tax NPV5% of US$3.85B (US$2.29B at 8%).
• Bench-scale purification has already reached 5N+ (99.9992% carbon) at 2.60 ppm equivalent boron content through an acid-free process.

• Electra Therapeutics is targeting a $303 million IPO to advance ipsoprubart through Phase 2/3 development in sHLH and expand its precision immune-cell depletion platform.
• Ipsoprubart has shown compelling early efficacy, including 100% eight-week survival and response rates in 12 frontline malignancy-associated HLH patients.
• A constructive biotech IPO backdrop and strong underwriting syndicate provide a favorable setup, with Electra offering an attractive risk-reward profile ahead of Friday’s debut.

• Ribosomal readthrough remains clinically unproven in the US and Europe, as evidenced by PTC Therapeutics withdrawing its Translarna (ataluren) NDA in February 2026 after the FDA deemed the efficacy data insufficient, and the European Commission’s March 2025 non-renewal of its conditional approval. This leaves Eloxx’s exaluren (ELX-02) facing a steep regulatory climb.
• Eloxx’s immediate survival is secured with a $62.0 million cash runway as of June 30, 2026, following its $66.0 million public offering and Nasdaq uplisting in June 2026. This capital is sufficient to fund operations past the mid-2027 Phase 2b EXACT study 16-week placebo-controlled readout. However, the trial relies on an invasive primary endpoint (change in the degree of podocyte foot process effacement via kidney biopsies), representing a major enrollment and regulatory risk.
• The competitive bar in Alport syndrome is rising rapidly, led by ENYO Pharma’s non-bile acid FXR agonist, vonafexor. In January 2026, ENYO reported Phase 2 Alpestria-1 data showing vonafexor reversed historical mean eGFR decline from -6.4 mL/min/1.73 m²/yr to an on-treatment functional gain of +4.8 mL/min/1.73 m²/yr. Eloxx will struggle to compete on efficacy without demonstrating equivalent renal function preservation.

• Agilent Technologies, Inc. reported a strong third quarter for fiscal 2026, with revenue reaching $1.88 billion and core year-over-year growth of 7.3%, exceeding guidance by 140 basis points.
• The company’s operating margin, excluding a $20 million tariff refund benefit, came in at 27.2%, surpassing expectations by 80 basis points.
• On an ex-refund basis, earnings per share (EPS) were $1.56, reflecting a 14% increase over the prior year and beating the high end of guidance by six cents.

• I haven’t written up an idea for a while, and this is a fairly simple one.
• It isn’t going to make anybody rich, but it could be valuable for those readers with smaller accounts.
• MiniMed (NASDAQ:MMED) is offering to exchange Medtronic (NYSE:MDT) shares for its own shares at a discount of 7%, subject to an upper limit of 4.5939 shares of Minimed per Medtronic share. 

• Veeva Systems reported its fiscal 2027 second quarter results with total revenue of $928 million, surpassing prior guidance, alongside non-GAAP operating income of $416 million.
• The company indicated strong execution across key segments, highlighting record performance in its Commercial segment, driven by broad-based growth in CRM, content, data offerings, and particularly the Crossix business unit.
• A significant strategic focus remains on artificial intelligence initiatives, notably the Veeva Falcon agentic labor platform.